SCHEMBL11063403

SCHEMBL11063403

CS(=O)(=O)c1cc2c(c(C(=O)O)c1)OCCO2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.45
LMNA P02545 4/20 0.44
ALDH1A1 P00352 6/20 0.42
KDM4E B2RXH2 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PTGS2 P35354 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK1 P28482 1/20 0.35
ATM Q13315 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11270751 0.85 ALDH1A1 (0.40) ALDH1A1KDM4EL3MBTL1POLBTDP1
SCHEMBL11062680 0.84 ALDH1A1 (0.42) LMNAALDH1A1KDM4EL3MBTL1POLB
SCHEMBL11152798 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EL3MBTL1POLBTDP1
SCHEMBL19186690 0.84 ALDH1A1 (0.42) LMNAALDH1A1KDM4EL3MBTL1POLB
SCHEMBL11259209 0.84 MEN1 (0.47) ALDH1A1KDM4EL3MBTL1POLBTDP1
SCHEMBL11151891 0.84 ALDH1A1 (0.45) LMNAALDH1A1KDM4EL3MBTL1POLB
SCHEMBL11266948 0.80 ALDH1A1 (0.46) LMNAALDH1A1KDM4EL3MBTL1SMN1; SMN2
SCHEMBL4739386 0.80 LMNA (0.46) BRD4LMNAALDH1A1KDM4EL3MBTL1
SCHEMBL10369313 0.80 SMN1; SMN2 (0.43) ALDH1A1PKMSMN1; SMN2RAB9AMEN1
SCHEMBL10368892 0.79 SMN1; SMN2 (0.45) ALDH1A1PKMSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011072174-A1 THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION AGIOS PHARMACEUTICALS, INC. (US) 2011-06-16 WO disclosed
US-4459300-A ANTIEMETICS, GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS BEECHAM GROUP P.L.C. (GB) 1984-07-10 US disclosed
EP-0069482-A1 Azabicycloalkyl benzamides, process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1983-01-12 EP disclosed